Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 4Phase NA 3Phase 3 3Phase 1/2 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 7Plasma cell 4Myeloid 3Sarcoma 2Gastrointestinal 2Gynecologic 1CNS 1

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 139Lenalidomide 75Cyclophosphamide 73Bortezomib 73Calcium Dobesilate 57fludarabine 49pomalidomide 43daratumumab 39fludarabine phosphate 34carfilzomib 33Melphalan 29dexamethasone acetate 24dexamethasone 21-phosphate 24auricularum 22Filgrastim 18Whole-Body Irradiation 15Biopsy 14ixazomib 13isatuximab 13Magnetic Resonance Spectroscopy 13Granulocyte Colony-Stimulating Factor 13Vorinostat 12Tacrolimus 12Specimen Handling 12Sirolimus 12Peripheral Blood Stem Cell Transplantation 12venetoclax 11belantamab mafodotin 11Rituximab 11Panobinostat 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × plerixafor × Plasma cell × Clear all
NCT01526096 2025-11-05

Stem Cell Transplantation for Patients With Multiple Myeloma

University of Chicago

Phase 1 Completed
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT03506802 2020-07-24

NYSCT MM

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT01610999 2017-05-09

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Tufts Medical Center

Phase 1 Terminated
7 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01074060 2013-02-15

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
18 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡